Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing.

@article{Narayan2012UltrasensitiveMO,
  title={Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing.},
  author={Azeet Narayan and Nicholas Carriero and Scott Gettinger and Jeannie Kluytenaar and Kevin R. Kozak and Torunn I. Yock and Nicole E. Muscato and Pedro Ugarelli and Roy H. Decker and Abhijit A. Patel},
  journal={Cancer research},
  year={2012},
  volume={72 14},
  pages={
          3492-8
        }
}
Detection of cell-free tumor DNA in the blood has offered promise as a cancer biomarker, but practical clinical implementations have been impeded by the lack of a sensitive and accurate method for quantitation that is also simple, inexpensive, and readily scalable. Here we present an approach that uses next-generation sequencing to quantify the small fraction of DNA molecules that contain tumor-specific mutations within a background of normal DNA in plasma. Using layers of sequence redundancy… 

Figures from this paper

Simple, multiplexed, PCR-based barcoding of DNA enables sensitive mutation detection in liquid biopsies using sequencing

The approach bridges the gap between the highly sensitive but specific capabilities of digital PCR, which only allows a limited number of variants to be analyzed, with the broad target capability of next-generation sequencing which traditionally lacks the sensitivity to detect rare variants.

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

It is envisioned that CAPP-Seq could be routinely applied clinically to detect and monitor diverse malignancies, thus facilitating personalized cancer therapy.

Characterization of Factors Affecting the Detection Limit of EGFR p.T790M in Circulating Tumor DNA

Both the sequencing platform and the specific nucleotide change affect the limit of detection and should therefore be determined in the validation process of new assays, supporting the approach to determine the detection limit.

CUT-PCR: CRISPR-mediated, ultrasensitive detection of target DNA using PCR

CUT-PCR was successfully applied to detect sequences with oncogenic mutations in the ctDNA of colorectal cancer patients’ blood, suggesting that the technique could be adopted for diagnosing various types of cancer at early stages.

Quantitative Identification of Mutant Alleles Derived from Lung Cancer in Plasma Cell-Free DNA via Anomaly Detection Using Deep Sequencing Data

This work detected epidermal growth factor receptor (EGFR) mutations in the plasma DNA of lung cancer patients using a semiconductor sequencer and a set of anomaly detection criteria based on a statistical model of the read error rate at each error position.

Single-tube, highly parallel mutation enrichment in cancer gene panels by use of temperature-tolerant COLD-PCR.

It is provided proof of principle that coamplification at lower denaturation temperature (COLD)-PCR technology enables multiplex low-level mutation detection in cancer gene panels while retaining throughput and facilitating detection and subsequent mutation sequencing.

Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq

The potential clinical utility of ctDNA analysis using CAncer Personalized Profiling by deep Sequencing (CAPP-Seq), a novel next-generation sequencing-based approach for ultrasensitive ct DNA detection, is focused on.

Pre-PCR Mutation-Enrichment Methods for Liquid Biopsy Applications

This review describes the available pre-PCR enrichment methods and focuses on the most recently developed techniques (NaME-PrO, UVME, and DEASH/MAESTRO), emphasizing their applications in liquid biopsies.

Biology of Human Tumors Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers : A Proof-of-Concept Study

Next-generation sequencing on cfDNA samples obtained from a consecutive series of patients for the screening of a range of clinically relevant mutations demonstrate the feasibility and potential utility of mutation screening in cfDNA using IonTorrent NGS for the detection of arange of tumor biomarkers in patients with metastatic lung cancer.

Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management

...

References

SHOWING 1-10 OF 46 REFERENCES

Detection of tumor mutations in the presence of excess amounts of normal DNA

A screening method, termed PPEM (PNA-directed PCR, primer extension, MALDI-TOF), that can detect as few as 3 copies of mutant alleles in the presence of a 10,000-fold excess of normal allele in a robust and specific manner and is amenable to high-throughput automation.

Detection and quantification of mutations in the plasma of patients with colorectal tumors.

  • F. DiehlM. Li B. Vogelstein
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 2005
Patients with advanced colorectal cancers consistently contained mutant adenomatous polyposis coli (APC) DNA molecules in their plasma, which has implications for the mechanisms through which tumor DNA is released into the circulation and for diagnostic tests based on this phenomenon.

Circulating mutant DNA to assess tumor dynamics

It is found that ctDNA measurements could be used to reliably monitor tumor dynamics in subjects with cancer who were undergoing surgery or chemotherapy, and it is suggested that this personalized genetic approach could be generally applied to individuals with other types of cancer.

Detection and quantification of rare mutations with massively parallel sequencing

An approach that can substantially increase the sensitivity of massively parallel sequencing instruments for the identification of rare variants and the utility of this approach for determining the fidelity of a polymerase, the accuracy of oligonucleotides synthesized in vitro, and the prevalence of mutations in the nuclear and mitochondrial genomes of normal cells is described.

LigAmp for sensitive detection of single-nucleotide differences

The LigAmp assay for sensitive detection and accurate quantification of viruses and cells with single-base mutations may find applications in the diagnosis of genetic disorders and the management of patients with cancer and infectious diseases.

Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer.

Results indicate mutant K-ras DNA is readily detectable by PCR in the plasma or serum of patients with advanced colorectal cancer, and plasma- or serum-based nucleic acid amplification assays may provide a valuable method of monitoring and potentially detecting coloreCTal cancer.

A highly sensitive assay for mutant ras genes and its application to the study of presentation and relapse genotypes in acute leukemia.

This assay was applied to DNA from four patients with relapsed acute leukemia in whom ras mutations present at diagnosis were not detectable by PCR/ASO hybridization at relapse, and loss of the mutation was confirmed, at a greatly increased sensitivity.

A highly sensitive assay for mutant ras genes and its application to the study of presentation and relapse genotypes in acute leukemia.

This assay was applied to DNA from four patients with relapsed acute leukemia in whom ras mutations present at diagnosis were not detectable by PCR/ASO hybridization at relapse, and loss of the mutation was confirmed, at a greatly increased sensitivity.

Detection of K-ras oncogene mutations by polymerase chain reaction-based ligase chain reaction.

To evaluate a rapid multiplexed assay to detect three common K-ras codon 12 mutations, primer pairs complementary to the wild-type and mutant loci were developed and tested with lung cancer cell

Circulating Nucleic Acids in Plasma and Serum

Nucleic acids have been detected in plasma, serum, urine, and other body fluids from healthy subjects as well as in patients and have now been shown to be useful in other conditions, such as diabetes mellitus, trauma, stroke, and myocardial infarction.